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with RLAI offers the potential for substantial cost savings in the
care of these patients.
PMH24
GEO OBSERVATIONAL STUDY: 24 MONTHS
CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL
STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH
OLANZAPINE AND HALOPERIDOL IN GERMANY
Eichmann F1, Reitberger U1, Clouth J2, Czekalla J2
1Kendle GmbH & Co GMI KG, Munchen, Germany; 2Lilly Deutschland
GmbH, Bad Homburg, Germany
OBJECTIVES: To describe real life disease characteristics, clini-
cal status and socioeconomics for schizophrenia in- and outpa-
tients treated with olanzapine or haloperidol over 24 months.
METHODS: GEO is a two-year prospective naturalistic study in
Germany. Quarterly observations were made for 308 patients
under olanzapine treatment and 188 patients under haloperidol
treatment. RESULTS: Compared to haloperidol patients, more
patients included into the study under olanzapine lived at home
without care (59% vs. 39%), were employed (35% vs. 17%),
and fewer were in early retirement (30% vs. 51%). During the
observational period, olanzapine and haloperidol treatment was
stable (olanzapine: 94% retention vs. haloperidol: 92%; dosage
changes occurred in 64% vs. 47%, respectively). Concomitant
medication related to schizophrenia was prescribed less fre-
quently for olanzapine patients (52% vs. 68%). Mean disease
severity, negative and cognitive symptoms as assessed by CGI
(scales from no symptoms (one) to very severe (seven)) ranged
between three and four. Positive and depressive symptom values
were lower (mean value between two and three). During the
course of the study disease severity improved for all symptoms
with slightly more improvement in olanzapine patients (mean
change in disease severity: olanzapine 0.95; haloperidol 0.76).
Throughout the 24-month period, olanzapine patients had lower
average EPS, parkinsonism, retardation, dyskinesia and akathisia
symptom scores (none (1) to severe (6)) than haloperidol patients
(mean EPS: olanzapine 1.3; haloperidol 2.0). Weight gain,
depression and other symptoms were reported more frequently
for olanzapine (<28% vs. <11%). Nevertheless, olanzapine
patients showed a lower mean Body Mass Index (BMI) than
haloperidol patients throughout the 24-month study period.
CONCLUSIONS: Schizophrenia patients under olanzapine
treatment showed a higher degree of integration into social and
occupational environment. For olanzapine patients, all schizo-
phrenia symptoms improved over time. Throughout the study,
olanzapine patients exhibited less EPS and had a lower BMI.
PMH25
EFFECTIVENESS AND TOLERABILITY OUTCOMES OF
RISPERIDONE LONG-ACTING INJECTION COMPARED TO
CONVENTIONAL DEPOT ANTIPSYCHOTICS IN A LARGE
CANADIAN PSYCHIATRIC HOSPITAL
Snaterse MH,Welch RP
Capital Health, Edmonton, AB, Canada
OBJECTIVE: To compare effectiveness and tolerability out-
comes of patients with schizophrenia treated with risperidone
long-acting injection and patients treated with conventional
depot antipsychotics. METHODS: Patients initiated on risperi-
done long-acting injection during a four-month index period
were compared to patients initiated on a conventional depot
antipsychotic during the same time period. Patient demograph-
ics including age, gender, diagnosis, number of previous psychi-
atric admissions and in-patient program were evaluated. The
effectiveness outcomes of antipsychotic polypharmacy, discharge
and readmission rates were compared. Neurological tolerability
was assessed as measured by the prescribing of regularly sched-
uled anticholinergic rescue medications. RESULTS: Forty
patients initiated on risperidone long-acting injection were com-
pared to 49 patients initiated on a conventional depot antipsy-
chotic. The two patient groups were demographically very
similar. The risperidone long-acting injection group was 75%
male with an average age of 41-years and 6.0 previous psychi-
atric admissions. The conventional depot group was 67% male
with an average age of 47.5 years and 5.9 previous psychiatric
admissions. Antipsychotic polypharmacy was reduced from 63%
to 31% in the risperidone long-acting injection group but
increased from 29% to 73% in the conventional depot group.
The use of anticholinergic rescue medications decreased from
47% to 12% in the risperidone long-acting injection group but
increased from 31% to 73% in the conventional depot group.
After 12-months of observation, 83% of the risperidone long-
acting injection patients had been discharged and none had been
readmitted, whereas 58% of the conventional depot group had
been discharged and, of those, 26% had already been readmit-
ted. CONCLUSION: In this difﬁcult-to-treat population of
patients, risperidone long-acting injection conferred signiﬁcant
advantages over conventional depot antipsychotics in terms of
effectiveness and tolerability. As well, the substantial differences
in discharge and readmission rates infer considerable phar-
macoeconomic advantages in favor of risperidone long-acting
injection.
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USING CLAIMS DATA TO ESTIMATE THE ANNUAL
PREVALENCE OF SCHIZOPHRENIA IN THE UNITED 
STATES, 2002
Wu EQ, Birnbaum HG,Aggarwal J, Moulis M
Analysis Group, Boston, MA, USA
OBJECTIVES: This study estimates the annual prevalence of
schizophrenia in the U.S. based on administrative claims data
analyses and a comprehensive literature review. METHODS:
The 2002 annual prevalence rate of schizophrenia in the U.S.
was estimated separately for privately insured, government
insured (Medicare, Medicaid), and uninsured populations. The
2002 annual prevalence for privately insured individuals was cal-
culated based on a de-identiﬁed administrative claims database
of approximately 3.0 million privately insured beneﬁciaries cov-
ering the period from 1999 to 2003. The 2002 prevalence of
Medicaid enrollees was calculated from Medi-Cal claims cover-
ing the period from 2000–2002. The 2002 schizophrenia preva-
lence in Medicare population was calculated as a weighted
average of the prevalence rates of Medicaid/Medicare dual eligi-
bles and private insurance program enrollees over 65. Published
statistics were used to estimate the prevalence of schizophrenia
in the uninsured population and to weight prevalence rates in
different populations to estimate the 2002 annual schizophrenia
prevalence in the general U.S. population. RESULTS: The annual
prevalence rate of schizophrenia in the U.S. in 2002 was esti-
mated at 0.5%. The Medicaid population was identiﬁed as
having the highest schizophrenia prevalence rate in the U.S.
(1.7% for non Medicare dual eligible enrollees), whereas annual
schizophrenia prevalence rates in Medicare and privately insured
population were 0.7% and 0.1%, respectively. The disease was
also more prevalent in the uninsured population (1.1%). Preva-
lence rates for women were highest in an older age group (56–65
years), whereas men’s prevalence rates peaked somewhat earlier
(46–55 years). CONCLUSIONS: The results suggest that schiz-
ophrenia may be more prevalent in the U.S. general population
than previously estimated in some epidemiology survey studies,
especially given the fact that claims database analyses usually
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provide lower bounds of prevalence estimates. Schizophrenia is
most prevalent in the low income and uninsured populations
than in the privately insured or Medicare populations.
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12-MONTH COST-EFFECTIVENESS ANALYSIS OF ORAL
ANTIPSYCHOTIC TREATMENTS IN PATIENTS 
WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN 
SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH 
OUTCOMES) STUDY
Knapp M1,Windmeijer F2, Haro JM3, Kontodimas S4, Brown J4,
Tzivelekis S4, Novick D4, Ratcliffe M4
1London School of Economics, London, UK; 2University of Bristol,
Bristol, UK; 3Sant Joan de Deu-SSM, Barcelona, Spain; 4Eli Lilly and
Company Ltd, Windlesham, Surrey, UK
OBJECTIVE: To determine the incremental cost-effectiveness for
treating schizophrenia patients with olanzapine versus risperi-
done, quetiapine, amisulpride, or oral typical antipsychotics.
METHODS: European SOHO is a 3-year, prospective, outpa-
tient, observational study associated with antipsychotic treat-
ment in 10 European countries. Health care resource use and
clinical effectiveness data were collected at baseline, 3, 6, and 12
months. Clinical effectiveness was assessed using the Clinical
Global Impression (CGI) scale. UK health care costs were applied
to resource use data for the 10 countries. Pair-wise incremental
costs and effectiveness were estimated between olanzapine-
treated patients and patients treated with each of the other oral
antipsychotics. Incremental cost-effectiveness ratios (ICERs)
were presented as the additional cost per CGI unit gained.
RESULTS: A total of 10,972 patients were enrolled at baseline,
80% were eligible for analyses at 12 months. Pair-wise cost-
effectiveness comparisons, over 12 months, showed treatment
with olanzapine is more effective and less costly than quetiapine
and amisulpride. Treatment with olanzapine is more effective
compared to treatment with risperidone and marginally more
costly: £226 per patient over 12 months. The incremental cost-
effectiveness ratio was £1299 per additional decrease in CGI unit
gained. Treatment with olanzapine is more effective than oral
typical antipsychotics and marginal more costly: £849 per
patient over 12 months. The incremental cost-effectiveness ratio
for olanzapine versus oral typical treatment was £3166 per addi-
tional decrease in CGI unit gained. Treatment maintenance was
77% at 12 months with olanzapine, which was greater than that
for the other treatments. CONCLUSIONS: Olanzapine was cost
saving and more effective than treatment with quetiapine and
amisulpride. The cost-effectiveness of olanzapine compared to
respirodone and typicals depends on the value assigned to the
decrease in GCI unit gained. This needs to be considered,
however, in the context of treatment maintenance, which
favoured olanzapine.
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COST-EFFECTIVENESS ANALYSIS OF ZIPRASIDONE VERSUS
NO TREATMENT FOR SCHIZOPHRENIA RELAPSE
PREVENTION
Azanza JR1, Bernardo M2, Rubio-Terrés C3, Díez T4, Rejas J5
1University Clinic of Navarra, Pamplona, Pamplona, Spain; 2Hospital
Clinic i Provincial, Barcelona, Barcelona, Spain; 3HERO Consulting,
Madrid, Madrid, Spain; 4Pﬁzer Spain, Madrid, Madrid, Spain; 5Pﬁzer
Spain, Madrid, Spain
OBJECTIVE: The aim of this study was to estimate the cost-
effectiveness of treatment with ziprasidone vs. no-treatment
(placebo) for schizophrenia relapse prevention, in Spain.
METHODS: Treatment of schizophrenia was modeled over one
year, by means of a retrospective deterministic model, from the
National Health System (NHS) perspective (year 2005). The
primary outcome was the probability of relapse occurring within
a 52 weeks period of treatment with ziprasidone daily doses of
40–160mg vs. placebo. Data was obtained from a randomized,
double-blind, placebo-controlled clinical trial (N = 218 patients).
Antipsychotic cost, concomitant drugs to treat adverse events
(extrapiramidal symptoms, etc.) and medical costs associated to
adverse events were derived from the clinical trial results and
from a Spanish Health Cost database. The average cost of a
patient with acute psychosis relapse admitted to hospital in Spain
(€3421) was obtained from a retrospective analysis of medical
records of 200 patients admitted for acute psychosis in eight
Spanish hospitals (The Psychosp Study), previously published.
RESULTS: The probability of psychosis relapse was 0.77 with
placebo, and 0.43, 0.35, 0.36 and 0.38 for ziprasidone daily dose
of 40, 80, 160mg or weighted doses, respectively (p < 0.01 vs.
placebo in all cases). The number needed to treat (NNT) to avoid
1 relapse was 1.3 (95% CI 1.2–1.4), 2.3 (2.0–2.8), 2.9 (2.4–3.7),
2.8 (2.2–3.3), and 2.6 (2.2–3.3), respectively. The yearly average
incremental cost per relapse avoided was €186 for the weighted
dose of ziprasidone, and ranged from savings of €557 
(80mg/day) to incremental of €1015 (160mg/day), lower in all
cases than the cost of a relapse (€3421). CONCLUSIONS:
According to this evaluation, and compared with no treatment,
the psychosis relapse prevention with ziprasidone is cost-
effective from the Spanish NHS perspective.
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DRUG UTILIZATION PATTERNS AND COSTS AND TOTAL
COSTS OF SCHIZOPHRENIA TREATMENT IN AN INSURED
POPULATION
Wilson L, Lightwood J, Le A, Gitlin M
University of California, San Francisco, San Francisco, CA, USA
OBJECTIVES: Schizophrenia is a chronic, disabling and costly
disease which affects 2.2 million in US. No study has looked at
the patterns of drug therapy and cost of the disease in a previ-
ously insured population and how closely treatment guide-
lines are followed. Problem: Using data from Blue Shield of 
California, we determine drug utilization patterns and costs and
the relationship between these patterns and the American Psy-
chiatric Association treatment guidelines and total costs of schiz-
ophrenia treatment. METHODS: We used claims data from Blue
Shield of California during 2001–2004 to select all patients with
ICD-9 diagnoses of schizophrenia. Data was available for uti-
lization and costs of health care use, including mental health
carve-out care. We used a 6 month run-in and ending period in
case of incomplete claims data. Drug categories were typical and
atypical antipsychotics and mood stabilizers. Drug patterns were
monotherapy, combination therapy with and without mood sta-
bilizers, and several switch patterns. We used chi-square tests and
linear regression analysis to detect associations between utiliza-
tion patterns and costs. RESULTS: The 799 schizophrenia
patients had a mean age of 42.6 years (20.4–86.2) and 46.3%
were males. Total annual direct costs of treatment were
$6301/patient, 46% acute care services, and 45% prescription
drugs. The combination treatment group (2 antipsychotics/mood
stabilizer) as well as a monotherapy group (one switch antipsy-
chotic therapy) had the highest utilization and costs. Our regres-
sion showed higher total costs correlated with males and patients
with an average of 1.8 therapy switches while on otherwise single
stable antipsychotic therapy. Older patients and those on a mood
stabilizer contributed the least to cost. CONCLUSION: The
total annual costs of these insured schizophrenic patients
($6301) were substantially lower than the $25,940 reported for
Medicaid patients. Health care utilization and costs increased as
